KorrekturOpen Access
Correction to ‘Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group)’
Liver International · 2026-06 · 46 (6)
DOI: 10.1111/liv.70685 ↗Kurz gefasst
Korrektur in der Zeitschrift Liver International, online erschienen am 09.05.2026. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Correction to ‘Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group)’. Liver International, 46(6). https://doi.org/10.1111/liv.70685
Vancouver
Correction to ‘Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group)’. Liver International. 2026;46(6). doi:10.1111/liv.70685
BibTeX
@article{euvimed2026,
title = {Correction to ‘Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group)’},
journal = {Liver International},
year = {2026},
volume = {46},
number = {6},
doi = {10.1111/liv.70685}
}
EUVIMED